IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10166252 B1

PDFFull Text
Date of Patent:
Jan. 01, 2019

Filed:

Apr. 14, 2015

Method for assessing and treating or preventing impaired plasma polar lipid levels

Applicant:

N.v. Nutricia, Zoetermeer, NL;

Inventor:

Nick Van Wijk, Utrecht, NL;

Assignee:

N.V. NUTRICIA, Zoetermeer, NL;

Attorneys:

Gilberto M. Villacorta

Sunit Talapatra

Foley & Lardner LLP

Primary Examiner:

Raymond J Henley, III

Int. Cl.
CPC ...
A61K 31/70 (2006.01); A61K 31/44 (2006.01); A61K 31/355 (2006.01); A61K 31/34 (2006.01); A61K 31/20 (2006.01); A61K 31/714 (2006.01); A61K 31/095 (2006.01); A61K 31/14 (2006.01); A61K 31/202 (2006.01); A61K 31/375 (2006.01); A61K 31/4415 (2006.01); A61K 31/519 (2006.01); A61K 31/7072 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
A61K 31/714 (2013.01); A61K 31/095 (2013.01); A61K 31/14 (2013.01); A61K 31/202 (2013.01); A61K 31/355 (2013.01); A61K 31/375 (2013.01); A61K 31/4415 (2013.01); A61K 31/519 (2013.01); A61K 31/7072 (2013.01); A61K 45/06 (2013.01);
Abstract

The invention pertains to the use of a preparation for the manufacture of a composition for preventing or treating impaired plasma levels of one or more polar lipids such as phosphatidylcholines [PC] selected from the group consisting of phosphatidylcholine diacyl C36:6 [PC aa C36:6], phosphatidylcholine diacyl C38:0 [PC aa C38:0], phosphatidylcholine diacyl C38:6 [PC aa C38:6], phosphatidylcholine diacyl C40:6 [PC aa C40:6] and phosphatidylcholine acyl-alkyl C40:6 [PC ae C40:6] in a preclinical AD or MCI subject or a subject with a high likelihood of developing AD or MCI, and wherein said subject is administered with a composition comprising at least one, preferably at least two, most preferably all B vitamins selected from the group consisting of vitamin B6, vitamin B12 and vitamin B9.

Find Patent Forward Citations

Loading…